Biotech Co.* |
Pharma Co. |
Type/Product Area | Terms/Details (Date) |
Ablynx NV* |
Procter & Gamble Co. |
They extended existing deal to include metabolic disease targets provided by P&G |
Ablynx is entitled to R&D funding, milestone payments and royalties on resulting products; it is using its Nanobody platform in the effort (4/10) |
Advanced |
Battelle |
Deal to develop monoclonal antibodies to treat humans and animals exposed to anthrax and plague, as well as for autoimmune diseases |
They entered a memorandum of understanding as a basis for jointly participating in the Initiatives for Proliferation Prevention projects of the U.S. Department of Energy (3/22) |
Affymetrix |
Abbott Molecular |
Abbott got nonexclusive rights to a number of Affymetrix patents |
The patents will allow Abbott to make and sell comparative genomic hybridization microarrays, related readers and software in the research and diagnostics field (4/5) |
Amgen Inc. |
Alcon Inc. |
Deal to research, develop and market therapeutics for treating eye diseases; the deal covers multiple targets and indications |
Amgen will provide molecules to the effort, while Alcon would get exclusive rights to resulting candidates in ophthalmology; Amgen either could share profits on resulting products or be entitled to milestone and royalty payments (4/24) |
Argos |
Beckman Coulter Inc. |
Argos got exclusive therapeutic use rights for the soluble protein CD83 |
Terms include use as a therapy for autoimmune disorders and transplant rejection; Beckman retained rights to CD83 in diagnostics; terms were not disclosed (4/26) |
Argos |
Novo Nordisk A/S (Denmark) |
Novo got rights to antibody technology designed to treat systemic immune disorders, including lupus |
Argos will get up to $69M in up-front and milestone payments, in addition to royalties on any resulting sales (3/14) |
Arius |
Takeda Pharmaceutical Co. Ltd. (Japan) |
Collaboration to use Arius' FunctionFIRST platform to discover treatments for human diseases |
Arius gets a $1M access fee and a $1M equity investment up front and research funding for three years; it also is entitled to milestone and royalty payments based on any licensed products (4/3) |
Artemis |
Bristol-Myers Squibb Co. |
Deal under which Artemis will generate genetically engineered murine models carrying selected genetic mutations |
BMS will use the models for validating drug screening targets; Artemis will do certain work with partner Taconic Farms Inc. (2/28) |
AVI BioPharma |
Cook Group Inc. |
Cook licensed AVI's Neugene antisense technology for down- regulating c-myc gene expression in the field of cardiovascular disease |
Cook will take over development of AVI's device- related programs for cardiovascular restenosis; Cook will buy $5M of AVI stock; AVI also would get double-digit royalties and a commercialization milestone payment (3/13) |
BG Medicine |
Mitsubishi Pharma Corp. (Japan) |
Deal for a preclinical study into the biochemical origins of muscle toxicity and associated biomarkers |
BG Medicine will apply its toxicology platform in the study of two lipid-lowering compounds; they will jointly own certain rights to resulting data (3/28) |
Biogen Idec |
Astellas Pharma US Inc. |
Astellas is buying worldwide rights to Amevive, a drug approved for treating plaque psoriasis |
Biogen gets $60M and undisclosed royalties under the deal, which covers all indications; it also will continue to manufacture the product (4/3) |
Biosite Inc. |
Eli Lilly and Co. |
Biosite will develop a diagnostic for measuring Protein C levels for trials of Lilly's sepsis drug, Xigris |
Lilly will use the test in enrollment for an upcoming Phase IIb trial; Biosite gets rights to resulting technology in sepsis diagnosis; terms were not disclosed (3/20) |
BioSystems |
AstraZeneca plc (UK) |
BSI will perform biomarker discovery services for AstraZeneca in osteoarthritis |
BSI retains rights to diagnostic applications; AstraZeneca gets nonexclusive rights to use results for R&D activities and exclusive rights to any new targets (2/23) |
Cell Signaling |
AstraZeneca plc (UK) |
CST will identify phosphorylation profiles and biomarkers of kinase-targeted lead compounds for AstraZeneca |
It is the third agreement in the area between the companies; terms of the deal were not disclosed (4/12) |
ChemDiv Inc.* |
Berlex Inc. (unit of Schering AG; Germany) |
Collaboration to discover lead compounds against several selected GPCR targets |
ChemDiv will apply its chemistry capabilities in the deal, terms of which were not disclosed (3/10) |
Codexis Inc.* |
Schering-Plough Corp. |
Deal to improve biocatalyst productivity at Schering- Plough using Codexis' MolecularBreeding platform |
Codexis will receive research funding and could get milestone payments in the deal (3/21) |
Crucell NV |
UCB SA (Belgium) |
UCB got rights to evaluate the PER.C6 cell line for research and manufacturing of monoclonal antibodies |
Terms of the deal were not disclosed (3/14) |
Crucell NV |
UMN Pharma (Japan) |
UMN Pharma got rights to use the PER.C6 cell line in development of a fusion protein for treating various diseases |
Crucell and DSM get a signing fee and annual maintenance fees, as well as fees for services; UMN's focus is on muscular dystrophy and metabolic diseases (3/9) |
Cytori |
Olympus Corp. (Japan) |
Olympus got an option to use adipose stem and regenerative cells for a specific area outside of cardiovascular disease |
Olympus is paying $1.5M for the exclusive right to negotiate a deal in that area; further terms were not disclosed (2/23) |
DigitalBiotech |
Grunenthal GmbH (Germany) |
Collaboration to discover and develop vanilloid receptor antagonists for treating pain |
Grunenthal will fund research and would market resulting products; terms were not disclosed (3/21) |
Elixir |
Kissei Pharmaceutical Co. Ltd. (Japan) |
Elixir got North American rights to the insulin secretagogue Glufast, which is on the market in Japan |
The product targets Type II diabetes; Kissei is entitled to milestone and royalty payments in the deal (3/27) |
Emisphere |
Novartis AG (Switzerland) |
Novartis executed its option to develop an oral parathyroid hormone using Emisphere's eligen delivery technology |
Emisphere is eligible for milestone payments of up to $30M, as well as royalties on resulting sales (3/8) |
Entelos Inc.* |
Johnson & Johnson Pharmaceutical Research & Development LLC |
They expanded collaboration to include multiple therapeutic areas over a five-year term |
Entelos is applying its PhysioLab platform, which simulates human biology, to programs at J&J; terms of the deal were not disclosed (3/16) |
Exelixis Inc.(EXEL) |
Daiichi Sankyo Co. Ltd. (Japan) |
Collaboration to discover and market therapies targeted against the mineralocorticoid receptor, which is implicatedin certain cardiovascular and metabolic diseases |
Exelixis gets $20M in up-front and research funding, as well as potential milestone payments and double-digit sales royalties; Exelixis said it would get $70M in guaran- teed near term payments and could get $1B in milestone payments (3/20) |
FivePrime |
Boehringer Ingelheim GmbH |
Two-year, multiproduct deal to develop therapeutics for rheumatoid arthritis and other diseases |
FivePrime gets an up-front fee and research support in the potential $75M deal and could get milestone and royalty payments; BI gets exclusive rights to resulting products (4/25) |
Galapagos NV (Belgium; Euronext:GLPG) |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Deal under which Galapagos will supply Roche with exclusive chemical compound libraries |
The three-year deal involves Galapagos' BioFocus division; terms were not disclosed (3/28) |
GeneGo Inc.* |
Berlex Inc. (unit of Schering AG; Germany) |
Berlex got rights to use the MetaCore platform for analysis of gene expression and other high- throughput data |
Berlex got rights in multiple therapeutic areas, including diagnostics; terms of the deal were not disclosed (3/13) |
Gene Logic |
NV Organon (the Netherlands) |
Deal to seek alternative development paths for drug candidates previously discontinued by Organon |
Gene Logic will use its repositioning technology to seek new uses for the compounds, for which Gene Logic could earn milestone payments; resulting candidates would be equally owned (4/21) |
Genentech |
BioWa Inc. (unit of Kyowa Hakko Kogyo Co. Ltd.; Japan) |
Genentech got exclusive rights to use Potelligent technology for multiple antibodies |
The technology is designed to improve the activity of antibodies; BioWa gets technology access fees and could get milestone and royalty payments (3/24) |
Idenix |
Novartis AG (Switzerland) |
Novartis exercised its option to license valopicitabine (NM283), an oral agent in Phase IIb trials for treating hepatitis C |
Idenix gets $25M up front and $45M more upon the start of Phase III trials in the U.S.; Idenix could get up to $455M in milestone payments; Idenix would co-promote the drug in the U.S. and the five major European markets (3/29) |
IDM Pharma |
Medison Pharma (Israel) |
Medison got rights in Israel to Junovan, an immune system stimulator for treating cancer |
IDM gets an up-front license fee and would get a milestone payment upon approval in Israel, as well as royalties on sales (3/14) |
ImQuest |
Samjin Pharmaceutical Co. Ltd. (South Korea) |
ImQuest got rights outside Korea to Samjin's piperazine series of anticancer compounds |
There are 105 compounds included in the deal, some at the late preclinical stage; terms were not disclosed (4/26) |
ImQuest |
Samjin Pharmaceutical Co. Ltd. (South Korea) |
ImQuest got rights to the entire pyrimidinedione series of anti-HIV compounds discovered by Samjin |
The deal follows one from January under which ImQuest agreed to provide development support to Samjin; terms were not disclosed (2/28) |
Infinity |
Novartis AG (Switzerland) |
Deal to discover and commercialize drugs targeting Bcl-2 protein family members for treating a range of cancers |
Infinity gets $30M up front, along with an equity investment and committed research funding over two years; with milestones, total payments could exceed $400M; Infinity also would get royalties on sales and another equity investment if it goes public and has a U.S. co-promotion option (3/6) |
Innate |
Novo Nordisk A/S (Denmark) |
Collaboration to develop drugs targeting natural killer cells, for a variety of indications |
Innate is getting an €8M equity investment and is entitled to €25M in up-front R&D and preclinical milestone payments over a three-year term; it also could get €25M in milestone payments per compound and royalties on resulting sales (4/5) |
Medarex Inc. |
Ono Pharmaceutical Co. Ltd. (Japan) |
Collaboration to develop a fully human antibody against stromal cell-derived factor 1 for multiple indications |
They will share costs through Phase II trials, after which each would be responsible in its own territories: Medarex in North America and Ono elsewhere (3/28) |
Memory |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Expanded deal gives Roche worldwide rights to nicotinic alpha-7 receptor compounds, excluding MEM 3454, which remain subject to the original option agreement |
Memory could receive $2.3M in research funding during 2007 and is entitled to additional milestones payments; Memory will conduct Phase I trials for resulting compounds, while Roche would be responsible for later-stage development and commercialization (2/28) |
MorphoSys |
Daiichi Sankyo Co. Ltd. (Japan) |
Collaboration to develop antibodies based on MorphoSys' HuCAL Gold technology |
Daiichi will start one antibody program and has an option on further programs; MorphoSys gets an up-front payment and research funding and could get licensing, milestone and royalty payments (3/16) |
MorphoSys |
F. Hoffmann- La Roche Ltd. (Switzerland) |
MorphoSys will generate antibodies against oncology targets provided by Roche |
The deal covers two antibody programs; MorphoSys gets an up-front payment and could get research funding and milestone payments totaling more than €10M per program, plus royalties on sales (3/1) |
Myogen Inc.z |
GlaxoSmithKline plc(UK) |
Two-part collaboration in pulmonary arterial hypertension: GSK got rights outside the U.S. to ambrisentan, while Myogen gained U.S. marketing responsibility for GSK's Flolan |
Myogen gets $20M up front and up to $80M more in milestone payments; it would get royalties averaging in the mid-20% range; under the three-year Flolan deal, which has a renewal option, Myogen will build a sales organization (3/6) |
Myriad |
Abbott Laboratories |
Five-year agreement to identify therapeutic targets for a variety of diseases |
Myriad will receive about 40% of the targets with associated lead compounds identified under the deal, and Abbott about 60%; terms were not disclosed (4/11) |
Nabi Bio- |
Fresenius Biotech GmbH (Germany) |
Nabi gets exclusive rights in the U.S. and Canada to ATG- Fresenius S, a polyclonal antibody for use in transplant rejection |
Fresenius will get up to $1M in development milestones and would get $4M upon FDA approval; it also would get royalty payments (4/3) |
Nanogen Inc. |
Fisher Scientific International Inc. |
Deal to expand the use of markers and diagnostic assays from Athena Diagnostics Inc. |
Fisher had just acquired Athena when the deal was made with Nanogen; Fisher made a $15M equity investment in Nanogen; further terms were not disclosed (3/16) |
Nastech |
Novo Nordisk A/S (Denmark) |
They entered a multi-compound, feasibility study agreement covering certain Novo compounds |
The compounds, indications and terms of the deal were not disclosed (3/15) |
Neuromed |
Merck & Co. Inc. |
Merck got worldwide rights to compounds for treating pain and other neurological disorders, including the Phase II product NMED-160 |
Neuromed gets a $25M payment up front and at least two years of research funding; milestone payments would total $202M if NMED-160 was launched in one indication and would total $450M if additional drugs and indications are developed; Neuromed would get royalties on any sales and has certain U.S. co-promotion options (3/20) |
NicOx SA |
Merck & Co. Inc. |
Collaboration to develop antihypertensive drugs using NicOx's nitric oxide-donating technology |
NicOx gets $11.2M up front and could get milestone payments of $340.2M, as well as royalties on resulting sales; it also retained certain co-promotion options in the U.S. and Europe (3/21) |
NicOx SA |
Pfizer Inc. |
Pfizer got exclusive rights across the entire field of ophthalmology to use NicOx's nitric oxide-donating technology |
NicOx gets €8M up front and a €15M equity investment at a 4.9% premium; NicOx also could earn milestone payments of €102M for the first ophthalmology program and up to €194.3M more if an indication outside ophthalmology is developed; NicOx also would get royalties on sales (3/2) |
Noxxon |
Pfizer Inc. |
Collaboration to develop products based on Noxxon's Spiegelmer technology; Pfizer also got rights to the preclinical product NOX- 11, a ghrelin-binding agent for obesity |
Noxxon gets up-front payments for each deal, and could get milestone and royalty payments; Pfizer also will make an equity investment in Noxxon; Pfizer will have the option to collaborate on up to three targets per year in the first collaboration (3/23) |
OriGene |
Bayer HealthCare AG (Germany) |
Bayer acquired access to OriGene's collection of full-length cDNA clones |
Bayer got access to OriGene's TrueClone Collection; terms of the deal were not dis- closed (3/13) |
OrthoLogic |
Quintiles Transnational Corp. |
Deal for the development and commercialization of Chrysalin (TP508), a synthetic peptide from OrthoLogic |
Quintiles will exclusively provide clinical research services, and will have the right of first negotiation to promote Chrysalin upon FDA approval; OrthoLogic also will receive an equity investment of up to $5M (2/28) |
Paratek |
Merck & Co. Inc. |
Worldwide deal to develop Paratek's PTK 0796, a broad- spectrum antibiotic in Phase I trials |
Paratek gets an up-front payment and could receive up to $127M in milestone payments through approval; it also would get royalties on sales and has a option to co-promote the I.V. formulation in the U.S. (3/9) |
Pharmacopeia |
Bristol-Myers Squibb Co. |
Pharmacopeia got rights to BMS compounds that possess dual angiotensin and endothelin receptor antagonist activity |
Pharmacopeia will provide BMS with a set of compound libraries; BMS is entitled to milestone and royalty payments under the exclusive, worldwide licensing deal (4/3) |
Pharmacopeia |
GlaxoSmithKline plc (UK) |
Deal under which Pharmacopeia will discover molecules for development by GSK in multiple therapeutic areas |
GSK gets exclusive options to conduct Phase III trials and to commercialize resulting products; Pharmacopeia gets $15M in the deal and could get up to $83M in milestones, plus double-digit royalties, on each resulting product (3/30) |
Pieris |
GE Healthcare |
Collaboration to discover targeted in vivo diagnostic and medical imaging compounds |
Pieris will use its Anticalin technology to select protein ligands to two targets selected by GE, which then could develop resulting imaging agents; Pieris retains therapeutic rights; terms were not disclosed (4/24) |
Praecis |
GlaxoSmithKline plc (UK) |
Praecis will apply its Direct- Select technology to identify small- olecule drug candidates against four GSK targets |
GSK has an option to enter a deal on resulting lead compounds; Praecis is getting a $0.5M equity investment and could get $1M in milestone payments during the pilot phase of the deal (4/10) |
ProMetic Life Sciences Inc. |
Sartorius AG (Germany) |
Collaboration to use bioseparation systems to recover proteins from human blood plasma |
They also will combine membrane and ligand technologies for expanded product offerings; terms were not disclosed (4/3) |
PsychoGenics |
Sosei Co. Ltd. (Japan) |
Collaboration to discover and develop therapies for central nervous system diseases |
Each will bring technologies to the effort, which focuses on Sosei compounds was previously discontinued; terms were not disclosed (4/10) |
PTC |
Schering-Plough Corp. |
Collaboration to develop PTC's preclinical compounds for the oral treatment of hepatitis C and other viral diseases |
PTC gets $12M up front and research funding; with milestones, payments to PTC could exceed $200M; it also would get royalties on worldwide sales (3/20) |
Sepracor Inc. |
UCB SA (Belgium) |
UCB got exclusive rights in the U.S. to the antihistamine levocetirizine |
Separacor would get royalties on sales; UCB already sells the product in Europe, where Sepracor earns royalties (2/23) |
SGX |
Novartis AG (Switzerland) |
Deal to develop and market BCR-ABL inhibitors for treating drug- resistant chronic myelogenous leukemia |
SGX gets $25M up front in cash and the purchase of stock and two years of R&D funding; payments, including milestones, could total $515M; SGX also would get royalties on resulting sales (3/27) |
Signet |
Bayer Diagnostics Inc. |
Signet will conduct research on urinary trypsin inhibitor immunoassays discovered by Bayer |
Signet will evaluate the utility of the trypsin inhibitors as biomarkers for acute renal failure in pilot trials that are under way; terms were not disclosed (3/1) |
Sirna |
GlaxoSmithKline plc (UK) |
Collaboration to discover and market RNA interference-based therapeutics for respiratory diseases |
Sirna gets $12M up front in a cash payment and equity investment and could get more than $700M in milestone payments, as well as royalties on resulting sales; it also could receive manufacturing revenues (4/3) |
Spectrum |
Par Pharmaceutical Co. Inc. |
Collaboration under which Par got rights to develop and market generic drugs |
Spectrum will develop products, and Par would market them in the U.S.; Spectrum would get milestone payments for each successfully developed product, and share in any resulting profits (2/23) |
Stratagene |
Bayer HealthCare Corp. |
Bayer will purchase Mx3005P instrument systems for use in a new platform it is developing |
Stratagene will customize the instrument for use in the molecular diagnostics platform (3/14) |
Third Wave |
Mitsubishi Corp. (Japan) |
They formed a joint venture focused on clinical molecular diagnostics and pharmaco- genetics in Asia |
The focus is on accelerating and expanding development of products for the the Japanese molecular diagnostics market; Mitsubishi will own about 14% of Third Wave Japan when the deal closes (4/5) |
Tripos Inc. |
Abbott Laboratories |
Chemistry collaboration to expand Abbott's compound file collection |
They intend to design, synthesize and purify novel, drug-like compounds; terms were not disclosed (3/20) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.